LifePak/BioPhotonic Scanner

1. Smidt CR, Seidehamel RJ, Devaraj S, Jialal I. The effects of a nutritionally complete
dietary supplement (LifePak) on antioxidant status and LDL-oxidation in healthy
non-smokers. FASEB J 1999; 13:A546. (Abstract)
2. Smidt CR, Shieh D. Non-invasive, biophotonic assessment of skin carotenoids as a
biomarker of human antioxidant status. FASEB J 2003; 17: A1115. (Abstract)
3. Smidt, C. R. and Burke, D. S. Nutritional significance and measurement of
carotenoids. Current Topics in Nutraceutical Research. 2004; 2(2): 79-91.
4. C. R. Smidt, W. R. Gellermann and J. R. Zidichouski. Non-invasive Raman
spectroscopy measurement of human carotenoid status. FASEB 2004; 18(4): A480.
5. Kaats GR, Wise JA, Morin R, Pullin D, Squires W, Murrieta TG, Hesslink R.
Reductions in DEXA measurements of body fat with different levels of involvement
in a weight loss program using dietary supplements. Journal of the American
Nutraceutical Association 1 (2): 19 26, 1998.
6. Hata TR, et al. Non-invasive Raman spectroscopic detection of carotenoids in human
skin. J Invest Dermatology 2000; 115:441.
7. Ermakov et al. Resonance Raman detection of carotenoid antioxidants in living
human tissues. Optics Letters. 2001; 26(15): 1179-1181.
8. Ermakov IV, Ermakova MR, Gellermann W, Lademann J. Noninvasive selective
detection of lycopene and beta-carotene in human skin using Raman spectroscopy. J
Biomed Opt. 2004 Mar-Apr; 9(2):332-8.
9. Bhosale P, Ermakov IV, Ermakova MR, Gellermann W, Bernstein PS. Resonance
Raman Quantification of Nutritionally Important Carotenoids in Fruits, Vegetables,
and Their Juices in Comparison to High-Pressure Liquid Chromatography Analysis. J
Agric Food Chem. 2004 Jun 2; 52(11):3281-3285.
General Raman Spectroscopy Studies
10. Ermakov IG, McClane RW, Gellermann W. Resonant Raman detection of macular
pigments in the living human retina. Optics Letters. 2001; 26(4): 202-204.
11. Gellermann et al. In vivo resonant Raman measurement of macular carotenoid
pigments in the young and the aging human retina. J Opt Soc Am A. 2002; 19(6):
1172-1186.
12. Gellermann et al. Raman imaging of human macular pigments. Optics Letters 2002;
27(1): 833-835.

13. Bernstein et al. Resonance Raman measurement of macular carotenoids in normal

subjects and in age-related macular degeneration patients. Ophthalmology. 2002;
109(10): 1780-1787.
14. Ermakov I, Ermakova M, Gellermann W, Bernstein PS. Macular pigment Raman
detector for clinical applications. J Biomed Opt. 2004 Jan-Feb; 9(1):139-48.

CordyMax
15. Cao, Z. and Wen, Y. Therapeutic effect analysis of JinShuiBao capsule in treatment of
33 elderly senescent Xu-Zheng (Asthenia syndrome) patients. Journal of Applied
TCM 1, 32-33. 1993.
16. Chen D-G. Effects of Cs-4, Jinshuibao Capsules on quality of life of patients with
chronic heart failure. J of Administration of Traditional Chinese Medicine 1995; 5:403.
17. Han S-R. Experiences in treating patients of chronic bronchitis and pulmonary
diseases with Cs-4 capsules. (Jinshuibao). J Administration of Traditional Chinese
Med 1995; 33-4.
18. Xiao Y, Huang XZ, Chen G, Et Al. Increased aerobic capacity in healthy elderly
humans given a fermentation product of cordyceps Cs-4. Medicine and Science in
Sports and Exercise 1999; 31:S174 (Abstract).
19. Nicodemus KJ, Hagan RD, Zhu J, Baker C. Supplementation with Cordyceps Cs-4
fermentation product promotes fat metabolism during prolonged exercise. Medicine
and Science in Sports and Exercise 2001; 33:S 164 (Abstract).
20. Talbott SM, Zhu JS, Rippe JM. CordyMax Cs-4 enhances endurance in sedentary
individuals. Med Sci Sports Exerc 2001; 33 (Abstract).
21. Zhu J, Yin W, Nicodemus K, et al. CordyMax Cs-4 improves glucose metabolism.
FASEB J 2001; 15.
22. Zhu, J. S., Pei, Y., Xu, Z., Wang, B., and Rippe, J. CordyMax reduces serum oxidized
LDL-cholesterol and increases HDL-cholesterol in humans with reduced HDLcholesterol. 4-10-2003.
23. Zhu, JS, Rippe, JM. CordyMax Enhances Aerobic Capability, Endurance
Performance, and Exercise Metabolism in Healthy, Mid-age to Elderly Sedentary
Humans. FASEB J 2004; 18(5): A931.
24. Chen YP, et al. Comparison of treatment chronic renal failure 30 cases by hypha of
culture and natural cordyceps sinensis. Chinese Traditional and Herbal Drugs 1986;
17:256-258.
25. Guo Y-Z. Pharmaceutical Chemistry, Pharmacology and Clinical effects of
Cordyceps Fungus and its preparation Jin Shui Bao. J Modern Diagnostics
Therapeutics 1986; 1:60-65

26. Zhou L, Yang W, Xu Y, et al. Short-term curative effect of cultured Cordyceps

sinensis (Berk.) Sacc. Mycelia in chronic hepatitis B Chinese Journal of Integrative
Medicine 1990; 15:53-5, 65.
27. Geng S, Zhao-hun Y, Cu-Xin-chang. Treatment of Hyperlipidemia with Cordyceps
sinensis: A Double Blind Placebo Control Trial. Int J Orient Med. 1990; 15:77-80.
28. Lei Jian., et. al. Pharmacological study on Cordyceps sinensis (Berk) Sacc. and Ze-e
Cordyceps. Journal of Chinese Materia Medica, 1992; 17(6), 364-366, 384.
In association with: Guangdong Province Institute of Materia Medica, Guangzhou.
China.
29. Zhu JL, Liu C. Modulating effects of extractum semen Persicae and cultivated
Cordyceps hyphae on immuno-dysfunction of inpatients with posthepatitic cirrhosis.
Chinese Journal of Integrative Medicine 1992; 12:207-209, 195.
30. Jiang Y, et al. The Application of Cultivated Cordyceps Sinensis in Renal
Transplantation. Journal of Am. Soc. Nephrol 1994; 5:1016
31. Qin Nanping, et. al. Observation on the therapeutic effects of cultured Cordyceps
sinensis (Jin Shui Bao) in the treatment of 42 hyperlipidemics. J Admin of TCM
1995; 5:25-26.
In association with: Zhi-Jiang Province Traditional Chinese Medical Hospital
32. Geng S. Clinical Report of Jinshibao Capsule in Treating Hyperlipidemia. Journal of
Administration of TCM 1995; 5:12-13.
33. Mao-lu L, Jianping W. J. Jin Shui Bao Capsule as adjuvant treatment for acute stage
pulmonary heart disease: Analysis of therapeutic effect of 50 clinical cases.
Management Traditional Chinese Medicine 1995;5:28-29.
34. Jiang J., et. al. Summary of treatment of 37 chronic renal dysfunction patients with
Jin Shui Bao [Cordyceps sinensis Cs-4]. J Management Traditional Chinese
Medicine 1995; 5:23-24.
In association with: Departments of TCM and Nephrology Medicine Changzhou, The
First Peoples Hospital
35. Xu Z-Y, Song K, Cai W-R, Tang J. Analysis of the Therapeutic efficiency of Jin Shui
Bao capsules in treatment of respiratory diseases. Journal of Administration of TCM
1995; 5:29-30.
36. Tong Yanging. Clinical observations of Jin Shui Bao in the treatment of
Hyperlipidemia.. J Admin TCM 1995;5:7-8.
In association with: Department of Geriatrics, First Affiliated Hospital of Beijing
Medical University

37. Zhong Yi Yao Guan li Za Zhi, Wang Wei-Quan. Observations of effects of Jin Shui
Bao on SOD activity in COED patients. Journal of Administration of TCM 1995;5:
24-24.
In association with: Wu-Han General Hospital of War Industry.
38. Yang Q-Z. Clinical observation of treating advanced stage schistosomiasis
accompanying hemorrhage of upper digestive tract with tablet of Jin Shui Bao. J
Admin TCM 1995;5: 48-49.
39. Zhen L-H, Dan W-W. The Clinical Efficacy of Cordyceps sinensis Cs-4 Capsule in
Treating Chronic Bronchitis and its Effect on Pulmonary Function. J Management
Traditional Chinese Medicine 1995; 5:9-11.
40. Zheng X., et. al. Observation on the therapeutic effects of artificial Cordyceps in the
treatment of Chronic Bronchitis and its effects on Pulmonary Function. In:
Anonymous Collection of the basic medical and clinical studies of submerged culture
Cordyceps sinensis. 1995; [2]: 95-99.
In association with: Department of Traditional Chinese Medicine Second Affiliated
Hospital of Jiangxi Medical College.
41. Zhang Z., et. al. Clinical and Laboratory Studies of Jin Shui Bao in eliminating
oxygen free radicals in elderly senescent Xu-Zheng patientsJournal of Management
of Traditional Chinese Medicine 5 (supplement), 14-18. 1995.
In association with: Jiangxi Medical College affiliated The Second Hospital.
Department of Biochemistry, Jiangxi Medical College.
Supported by: National Nature Science Research Award.
42. Zhou D., et. al. Effect of Jin Shui Bao capsule on the immunological Function of 36
patients with advanced Cancer. <None Specified> 1995; 15:476-478.
In association with: The First Affiliated Hospital, Guangzhou University of TCM,
Guangzhou.
43. Bao T-T. Further study of pharmacological functions on JinShuiBao. J Admin of
TCM 1995; 5:6-6.
44. Li L, Zheng F, Xiao S, Tan B. Effects of cordyceps sinensis (CS) in real damage of
hemorrhagic fever with renal syndrome (HFRS). J Am Soc Nephrol. 1995; 6:469
(abst).
45. Tao A-H. From Cordyceps sinensis and better than Cordyceps sinensis. J Admin of
TCM. 1995; 5:20-21
46. Xu F. Amelioration of cyclosporin nephrotoxicity by cordyceps sinensis in kidneytransplanted recipients. Nephrol Dial Transplant: Letters. 1995;142-143.

47. Che YS, Lin LZ. Clinical Observation on Therapeutic effects of JinShuiBao on
coronary heart disease, hyperlipidemia, and blood rheology. Chinese Traditional
Herbal Drugs 1996; 27:9:552-553.
48. Guo Qingchang, et. al. Clinical observation of Jin Shui Bao capsule adjunctive
treatment of 20 diabetic patients. Journal of Management of Traditional Chinese
Medicine 5 (supplement): 22.
In association with: Dept. of Medicine, First Affiliated Hospital of the Tianjing
College of Traditional Chinese Medicine.
ANIMAL STUDIES
49. Dai GW, Bao.T.T., Xu CF, Cooper R, Et Al. Enhanced hepatic energy state in mice
after administration of a fermentation product of cordyceps Cs-4. Medicine and
Science in Sports and Exercise 1999; 31:S120 (Abstract).
50. Balon TW, Jasman AP, Zhu JS. A fermentation product of Cordyceps sinensis
increases whole-body insulin sensitivity in rats. J Altern Comp Med 2002; 8:315-23.
51. Zhao CS, Yin WT, Wang JY et al. CordyMax Cs-4 improves glucose metabolism and
increases insulin sensitivity in normal rats. J Altern Complement Med 2002; 8:30914.
REVIEW ARTICLES
52. Zhang H., et. al. Immunopharmacology of Cordyceps sinensis. Department of
Immunology, Anhwai Chinese Medicine University. A Review Journal of
TCM/Western Medicine Relationship.
53. Xu Fei. Artificially Cultured Mycelia of Cordyceps sinensis in Medical Use in China.
China Journal of Chinese Materia Medica, 1992; 27(4), 195-198.
In association with: Naval Medical Institute
54. Clinical Study of Cordyceps Sinensis capsules on the treatment of Chronic
Bronchitis. Jiang-Xi TCM Drugs Factory. Original application material. 1997; 1-6.
In association with: Department of Clinical Pharmacology, Institute of Materia
Medica, Beijing
55. Ding F., et. al. Current Situation of the Researches on Cordyceps Sinensis. Chinese
Journal of Biochemical Pharmaceutics, 1994; 15(4), 297-299.
In association with: Nanjing Biochemical Pharmaceutical Institute
56. Yang Z-H. Clinical Validity of Cordyceps Capsules in the Treatment of Chronic
Bronchitis: A summary. Collection on the basic medicinal and Clinical Studies of
Submerged Culture Cordyceps sinensis 1985:114-117.

57. Zhu, J. S., Halpern, G. M., and Jones, K. The scientific rediscovery of an ancient
Chinese herbal medicine:Cordyceps sinensis. Part I. J Altern.Complement Med. 1998;
4(3): 289-303.
58. Zhu JS, Halpern GM, Jones K. The scientific rediscovery of a precious ancient
Chinese herbal regimen: Cordyceps sinensis: part II. J Altern.Complement Med
1998;4: 429-57.

IgG Boost/Nutrimmune Chews

Note: Millions of dollars and several years were devoted to the development of the
Colostrum MFT technology. Even though most of the studies were not performed by
Pharmanex, Pharmanex now owns all of the intellectual property rights to this
technology and all of the research that was invested in it.
Colostrum MFT Research
59. D.M. Lyerly, E.F. Bostwick, S.B. Binion and T.D. Wilkins. Passive immunization of
hamsters against disease caused by Clostridium difficile by use of bovine
immunoglobulin G concentrate. Infect Immun 1991; 59:2215-2218.
60. C.O. Tacket, S.B. Binion, E.F. Bostwick, G. Losonsky, M.J. Roy and R. Edelman.
Efficacy of bovine milk immunoglobulin concentrate in preventing illness after
Shigella flexneri challenge. Amer J Trop Med Hyg 1992; 47:276-283.
61. N. Takahashi, G. Eisenhuth, I. Lee, C. Schachtele, N. Laible and S. Binion.
Nonspecific antibacterial factors in milk from cows immunized with human oral
bacterial pathogens. J Dairy Sci 1992; 75:1810-1820.
62. N. Takahashi. G. Eisenhuth, I. Lee, N. Laible, S. Binion and C. Schachtele.
Immunoglobulins in milk from cows immunized with oral strains of Actinomyces,
Prevotella, Porphyromonas and Fusobacterium. J Dent Res 1992; 71:1509-1515.
63. P.D. Greenberg and J.P. Cello. Treatment of severe diarrhea caused by
Cryptosporidium parvum with oral bovine immunoglobulin concentrate in patients
with AIDS. J AIDS and Hum Retrovirol 1996; 13:348-354.
64. C.P. Kelly, C. Pothoulakis, F. Vavva, I. Castagliuolo, E.F. Bostwick, J.C. O'Keane, S.
Keates and J.T. LaMont. Anti-Clostridium difficile bovine immunoglobulin
concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins.
Antimicrobial Agents and Chemother 1996; 40: 373-379.
65. C.P. Kelly, S. Chetham, S. Keates, E.F. Bostwick, A.M. Roush, I. Castagliuolo, J.T.
LaMont and C. Pothoulakis. Survival of anti-Clostridium difficile bovine
immunoglobulin concentrate in the human gastrointestinal tract. Antimicrobial Agents
and Chemother. 1997; 41: 236-241.
66. T.K. Graczyk, M.R. Cranfield, P. Helmer, R. Fayer, and E.F. Bostwick. Therapeutic
efficacy of hyperimmune bovine colostrum treatment against clinical and subclinical
Cryptosporidium serpentis infections in captive snakes. Vet. Parasitol 1998; 71:123132.

67. M. Warny, A. Fatimi, E.F. Bostwick, D.C. Laine, F. Lebel, J.T. LaMont, C.
Pothoulakis, C.P. Kelly. Bovine immunoglobulin concentrate-Clostridium difficile
retains C. difficile toxin neutralizing activity after passage through the human
stomach and small intestine. Gut 1999; 44:212-217.
68. J. Tollemar, N. Gross, N. Dolgiras, C. Jarstrand, O. Ringdn and L. Hammarstrm.
Fungal prophylaxis by reduction of fungal colonization by oral administration of
bovine anti-Candida antibodies in bone marrow transplant recipients. Bone Marrow
Transpl. 1999; 23:283-290.
69. T.K. Graczyk, M.R. Cranfield, and E.F. Bostwick. Hyperimmune bovine colostrum
treatment of moribund Leopard geckos (Eublepharis macularius) infected with
Cryptosporidium sp Vet Res 1999; 30:377-382.
70. R. A. Hoerr and E.F. Bostwick. Bioactive Proteins and Probiotic Bacteria: Modulators
of Nutritional Health. Nutrition 2000; 16:7-8.

ProBio PCC
71. Charteris WP, Kelly PM, Morelli L, Collins JK. Development and application of an
in vitro methodology to determine the transit tolerance of potentially probiotic
Lactobacillus and Bifidobacterium species in the upper human gastrointestinal tract.
J Appl Microbiol. 1998 May; 84(5):759-68.
72. Plant L, Conway PL. Association of Lactobacillus spp with Peyers Patches in mice.
Clinical and Diagnostic Immunology. 2002; 8(2): 320-324.
73. Plant L, C Lam, PL Conway, and K O'Riordan. Gastrointestinal microbial community
shifts observed following oral administration of a Lactobacillus fermentum strain to
mice. FEMS Microbiology Ecology. 2003; 43:133-140.
74. Gibson SAW, Conway PL. Recovery of a probiotic organism from human faeces after
oral dosing. In Human Health: The contribution of microorganisms in Springer Series
in Applied Biology, 1994, pp. 119143.
PUBLICATION PENDING
75. Conway PL, Blomberg L. Reduction in incidence and severity of diarrhea in soldiers
consuming Lactobacillus fermentum KLD. 2002. (Publication pending)
76. Li P, Conway PL. Effects of administration of Lactobacillus fermentum on faecal
microbes and symptoms in patients with irritable bowel syndrome. 2002.
(Publication pending)
77. Weilin A, Farthing M, Conway PL. Colonization of ileal mucosa by Lactobacillus
fermentum KLD in pouchitis patients after oral dosage. 2002. (Publication pending)
78. Conway PL. Effects Of Oral Administration Of The Probiotic Lactobacillus
Fermentum Vri-002 On The Immune System Of Endurance Athletes. (Publication
pending).
Presented at the Australian Conference of Science and Medicine in Sport October 79, 2004.

ReishiMax
79. Lua QY, Jin YS, Zhang QF, Zhang ZF, Heber D, Go VL, Li FP, Rao JY. Ganoderma
lucidum extracts inhibit growth and induce actin polymerization in bladder cancer
cells in vitro. Cancer Letters 2004; 216:920.
80. Jiang J, Slivova V, Harvey K, Valachovicova T, Sliva D. Ganoderma lucidum
suppresses growth of breast cancer cells through the inhibition of Akt/NF-kappaB
signaling.Nutr Cancer. 2004;49(2):209-16.
81. Daniel Sliva, Ph.D., Miroslav Sedlak, Ph.D. et al. Biologic Activity of Spores and
Dried Powder from Ganoderma lucidum for the Inhibition of Highly Invasive Human
Breast and Prostate Cancer Cells. The Journal of Alternative and Complementary
Medicine. 2003; 9(4): 491-497.
82. Veronika Slivova, BS; Tatiana Valachovicova, BS; Jia-Hua Jiang, PhD; Daniel Sliva,
PhD. Ganoderma lucidum inhibits invasiveness of breast cancer cells. Journal of
Cancer Integrative Medicine. 2004; 2(1): 25-30.
83. Ma, J., Ye, Q., Hua, Y., Decheng, Z., Cooper, R., Chang, M., Chang, J. Y., and Sun, H.
H. New lanostanoids from the mushroom Ganoderma lucidum. Journal of Natural
Products 2002; 65(1):72-75.
84. Yuan-Yuan Wang, Kay-Hooi Khoo, Shui-Tein Chen, Chun-Cheng Lin, Chi-Huey
Wong and Chun-Hung Lin. Studies on the Immuno-Modulating and Antitumor
Activities of Ganoderma lucidum (Reishi) Polysaccharides: Functional and Proteomic
Analyses of a Fucose-Containing Glycoprotein Fraction Responsible for the
Activities. Bioorganic & Medicinal Chemistry. 2002; 10:10571062.
85. Wen-Chuan Lin, Yue-Wen Wu, Ming-Chun Xie, Jia-Shi Zhu. ReishiMax protects the
liver and improves liver functions in an experimental hepatitis model. FASEB J
2004; 18(5): A999.
86. Jia-Hua Jiang, Veronika Slivova, et al. Ganoderma lucidum inhibits proliferation and
induces apoptosis in human prostate cancer cells PC-3. International Journal of
Oncology. 2004; 24:1093-1099.
87. C. Li, J. Yin, F. Guo, D. Zhang & H. Sun. Ganoderic Acid SZ, a New Lanostanoid
from the Mushroom Ganoderma Lucidum. Natural Product Research. 2004.
(Publication pending).

Cholestin
PHARMANEX SCIENTISTS
88. Heber,D.; Yip,I.; Ashley,J.; et al. A Chinese red yeast rice dietary supplement
significantly reduces cholesterol levels FASEB J 1998; 12:A206.
89. Rippe J, Bonovich K, Colfer H et al. A multi-center, self-controlled study of
Cholestin in subjects with elevated cholesterol. Circulation 1999; 99:1123.
90. Ma JY, Li YG, Ye Q, et al. Constituents of red yeast rice, a traditional Chinese food
and medicine. J Agric Food Chem. 2000; 48:5220-5.
91. Heber D, Lembertas A, Lu QY, Bowerman S, Go VL. An analysis of nine proprietary
Chinese red yeast rice dietary supplements: implications of variability in chemical
profile and contents. J Altern Complement Med. 2001; 7:133-9.
92. Heber D, Yip I, Ahsley JM, Elashoff DA, Elashoff RM, Go VL. Cholesterol-lowering
effects of a proprietary Chinese red-yeast rice dietary supplement (83 subjects). Am J
Clin Nutr 1999; 69:231-236.
93. Brown,D. Lipid-lowering Effects of Monascus Purpureus (Red Yeast) Rice.
Quarterly Review of Natural Medicine. 1993; pp. 103-104.
94. Li C, Li Y, Zhonglin H. Experimental studies on the toxicity of Xuezhikang.
Information of the Chinese Pharmacology Society 1995; 12:12-5.
95. Su MZ, et al. Clinical trial of Xue Zhi Kang capsules for treating hyperlipidemia
(116 subjects). New Traditional Chinese Medicines and Clinical Pharmacology 1995;
6(4):16-19.
96. Wang J, Lu Z, Chi J, Wang W. Clinical trial of extract of Monascus purpureus (red
yeast) in the treatment of hyperlipidemia. Chinese Journal of Experimental
Therapuetics for Prepared Chinese Medicine 1995; 1:1-5.
97. Liu ZM. The clinical observation of the medical treatment for hyperlipidemia with
Xue Zhi Kang (50 subjects)
Chinese Medical Information Guide Paper May
1996; 9: 12. In association with: Sino-Japanese United Hospital
98. Shen ZW. A prospective study on Zhitai capsule in the treatment of primary
hyperlipidemia (152 subjects). National Medical J China 1996; 76(2):156-157.
In association with: Beijing University Hospital
99. Chen,Q.S.; Qiang,Z.W.; Peng,Q.; et al. Clinical efficacy observation on a doubleblind, randomized controlled trial of Xue Zhi Kang for the treatment of patients with

hyperlipidemia in elderly. Chinese Journal of Internal Medicine. 1998; 37(6): 401402.

100.

Hua,X.F.; Yun,S.X.; Hui,W.X.; et al. Effects of Xue Zhi Kang on hyperlipidemia

treatment and body weight index. Chinese Journal of Internal Medicine. 1998;
37(6):403-405.

101.

Jin W, et al. A comparative study of Xuezhikang and Mei Bei Le (Mevinolin) in

treatment of essential hyperlipidemia (44 subjects). Chinese J of New Drugs
1997; 6(4): 265-268.
In association with: The First Hospital of Shanghai

102.

Kou,W-R.; Shi,X.; Lu,Z. The Therapeutic Effects of Xue Zhi Kang over 6
months and the Observation of its Safety. Chinese Journal of Internal Medicine
1998; 37(6): 406-407.
In association with: China Academy of Medical Science and Xie-He Medical University
103.

Lu GP. The comparison of the blood lipids lowering effects of Xue Zhi Kang and
Simvastatin on hypercholesterolemic patients (28 subjects).
Chinese J of
Internal Medicine June 1998; 37(6):371-373.
In association with: Rui-Jin Hospital, Shanghai Second Medical University

104.

Lu, Guoping, et al. Comparison of the effects of Xue Zhi Kang with simvastatin
on lipid profile modifications in patients with hypercholesterolemia. Chinese
Journal of Internal Medicine. 1998; 37(6):371-373.

105.

Lu ZL. Clinical evaluation of Xue Zhi Kang treatment of hyperlipidemia (121

subjects). Chinese J of Circulation 1997; 12(1):12-15.
In associtation with: Dept. of Coronary Heart Disease, Fu Wai Hospital, CAMS
and PUMC, Beijing

106.

Ping, K.L.; Yu, J.S.; Yun, S.X.; et al. Clinical observation on lipid long-term
profile modification between small-dose Xue Zhi Kang and simvastatin. Chinese
Journal of Internal Medicine. 1998; 37(6): 408.

107.

Pulin,Y.; Zhiwei,S.; Meizhen,S.; et al. A Clinical Study of Xue Zhi Kang on the
Treatment of Primary Hyperlipidemia. Chinese Circulation Journal 1997;
12(1):16-19.
In association with: Dept of Endocrine, Beijing Hospital

108.

Rong,K.W.; Yan,F. General review for basic and clinical researches on "Xue Zhi
Kang". Chinese Journal of Internal Medicine 1998 Jun; 37(6):364-366.

109.

Rong,K.W.; Yun,S.X.; Liang,L.Z.; Li,C. Observation on efficacy and safety of

Xue Zhi Kang. Chinese Journal of Internal Medicine. 1998; 37(6):406-407.

110.

Wang J, et al. Multicenter clinical trial of the serum lipid-lowering effects of a

Monascus purpureus (red yeast) rice preparation from traditional Chinese
medicine. (446 subjects). Curr Ther Res Clin Exp 1997; 58(12):964-978.
In association with: Dongzhimen Hospital, Beijing Traditional Chinese Medicine
University

111.

Xiang, Z.D.; Qiang, Y.J.; Jie,L.Y. Clinical efficacy observation on Xue Zhi Kang
for the treatment of hyperlipidemia. Chinese Journal of Internal Medicine. 1998;
37(6): 402-403.

112.

Xu,Cheng-Bin. Clinical Observation on long-term Lipids-Modulating Actions of

Xue Zhi Kang in Small Dosage. Chinese Journal of Internal Medicine 1998;
37(6): 405-406
'97 National Symposium for Cardiovascular and Cerebrovascular Clinical
Therapies
In association with: Dongzhimen Hospital, Beijing Traditional Chinese Medical
University

113.

Zhang,M-L.; Duan,Zhen-Wen; Xie,S.M. Research progress on the Effective

Constituents in Xue Zhi Kang. Chinese New Drugs Journal. 1998; 7(3): 213214.
Bonovich,K.; Colfer,H.; Petoskey,M.I., et al. A multi-center, self-controlled study
of Cholestin in subjects with elevated cholesterol. Journal of Investigative
Medicine 1999; 47(2):54A.

114.

115.

Jian,J.; Hao,X.Y.; Deng,C-Y.; et al. The effects of Xue Zhi Kang on serum lipid
profiles, thromboxane A2 and prostacyclin in patients with hyperlipidemia.
Chinese Journal of Internal Medicine 1999 Aug; 38(8):517-519.

116.

Li, WH.; He, DL.; Li, LH.; et al. Effects of Xue Zhi Kang on lipid profile
modification in 42 patients. Li Shizhen Medicine and Materia Research. 1999;
10(11):185.

117.

Qin SC, et al. Elderly patients with primary hyperlipidemia benefited from
treatment with a Monascus purpureus rice preparation: A placebo-controlled,
double-blind clinical trial. (70 subjects).
Circulation 1999; 8:1123, P89
(abstract).
Presented at American Heart Associations 39th Annual Conference. March 2427, 1999. Orlando, Florida.

118.

Qin SC, Zhang WQ, Qi P, et al. A Monascus purpureus rice preparation reduces
serum cholesterol and triacylglycerols in elderly with primary hyperlipidemia. J
Invest Med 1999; 47: 54A.

119.

Zhao,Z-m.; Wang,Y.; Jiang,Z-b.; et al. Effect of Xue Zhi Kang on vascular

endothelium dependent diastolic function of unstable angina pectoris patients with

normal cholesterol level. Journal of Integrated Traditional and Western Medicine.

1999; 19(11):667.
120.

Zhang, XY, et al. Observation on the efficacy of Xue Zhi Kang in treatment of
hyperlipidemia. Lishizhen Medicine and Materia Medica Research. 1999;
10(10):772-773

121.

Keithley, JK.; Swanson B.; Sha, BE.; Zeller, JM.; Kessler, HA,; Smith KY. A
Pilot Study of the safety and efficacy of cholestin in treating HIV-related
dyslipidemia. Nutrition 2002 Feb; 18(2):201-204.

ANIMAL STUDIES
122.

Kritchevsky D, Li C, Wei W and Wang Y. Influence of Monascus Purpureus

fermented rice (red yeast rice) on experimental atherosclerosis in rabbits. FASEB
J. 1998; 12(4): A206.

123.

Zeng, D. Serial studies on antiatherosclerotic mechanisms of Xue Zhi Kang.

Chinese Journal of Internal Medicine 1998; 37(6):367-370.

124.

Li C, Zhu Y, Wang Y, Zhu J-S, Chang J, Kritchevsky D. Monascus purpureusfermented rice (red yeast rice): A natural food product that lowers blood
cholesterol in animal models of hypercholesterolemia. Nutrition Research 1998;
18:71-81.

125.

Acute toxicity study of Xuezhikang in mice. (Unpublished). 1999. Beijing

Medical University.

126.

Wei W, Li C, Wang Y, Su H, Zhu J, Kritchevsky D. Hypolipidemic and antiatherogenic effects of long-term Cholestin (Monascus purpureus-fermented rice,
red yeast rice) in cholesterol fed rabbits. J Nutr Biochem 2003; 14:314-8.

REVIEW ARTICLES
127.

Chang M. Substantiation of Cholestin Claims Memorandum, February 4, 1997.

Pharmanex Internal Memo 1997; 1-8.

128.

Havel, RJ. Dietary supplement or drug? The case of Cholestin. Am J Clin Nutr
1999; 69:175-176.

Venix
129.

Yang WZ, Deng XA, Hu W. Clinical study of fermentation product of Cordyceps

Sinensis on treatment of Hyposexuality. JiangXi TCM. 1985; 5: 46-47.
In association with: Third Affiliated Hospital, Beijing Medical School,
Department of Drug Research; Jiangxi TCM Factory.

130.

Wan FC, Guo YZ, Deng XA. Sex Hormone-like Effects of JinShuiBao
[Cordyceps sinsensis Cs-4] Capsule: Phamacologic and Clinical Studies. ZhongCheng Drugs. 1988; 9: 29-31.

131.

Li CL, Wu ER, Zhu J-S, Chang J. A mixture of CordyMax and Ginkgo biloba
extract enhances erectile function in orchiectomized male rats. FASEB J 2001;15
(Abstract).

132.

Li CL, Wu ER, Zhu J-S, Chang J. Venix improves cognitive function in memoryimpaired and normal animal models. FASEB J 2001;15 (Abstract).